


AMENDMENTS TO THE CLAIMS

1. (currently amended) A compound having the formula:



and pharmaceutically acceptable salts, ~~esters and prodrugs~~ thereof; wherein:

~~W is [[and Z are independently OR² or]]~~ NR¹R² or NR¹ - (CR¹)_n - NR³R⁴;

Z is OR₂, NH₂, NR¹R² or NR¹ - (CR¹)_n - NR³R⁴;

wherein in NR¹R² and NR³R⁴, R¹ and R² together with N and R³ and R⁴ together with N may form an optionally substituted 5-6 membered ring containing N, O, or S;

A is H, halo or NR¹₂;

R¹ ~~[[is]]~~ and R³ are independently H or a C₁₋₆ alkyl;


R² is ~~[[H or]]~~ a C₁₋₁₀ alkyl or C₂₋₁₀ alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with a carbocyclic or C₃₋₆ cycloalkyl, aryl, or a 5-14 membered heterocyclic ring containing N, O, or S; or R² is an aryl, heteroaryl, or an optionally substituted 5-14 membered heterocyclic ring, aryl or heteroaryl containing N, O, or S;

R⁴ is H or a C₁₋₁₀ alkyl or C₂₋₁₀ alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with a carbocyclic or a 5-6 membered heterocyclic ring;

m is 1-2;

n is 1-6;

Y is selected from the group consisting of




where R^6 is a substituent at any position on the ring or fused ring; and is H, OR^1 , C_{1-6} alkyl, C_{2-6} alkenyl, each optionally substituted by halo, =O or one or more heteroatoms; or R^6 is an inorganic substituent; or two adjacent R^6 is linked to obtain a 5-6 membered substituted or unsubstituted carbocyclic or heterocyclic ring, optionally fused to an additional substituted or unsubstituted carbocyclic or heterocyclic ring;

Q is CH or N;


and X is O, NH, or S;

provided that W is not hydroxy or ethoxy when Y is 2-thiazolyl or Z is 3-amino-1-pyrrolidinyl.

2. (original) The compound of claim 1, wherein A is halo.
3. (original) The compound of claim 2, wherein said halo is fluoro.
4. (currently amended) The compound of claim 1, wherein Y has the formula



where X is S and each R_6 is H;
or the formula



where X is S, Q is CH, and each R_6 is H.

5. (original) The compound of claim 1, wherein W and Z are independently NR^1R^2 .
6. (currently amended) The compound of claim 5, wherein R^1 is H and R^2 is a C_{1-10} alkyl ~~optionally containing one or more heteroatoms, and optionally~~ substituted with an amine, a C_{3-6} cycloalkyl, aryl or a 5-14 membered heterocyclic ring containing one or more N, O or S.
7. (original) The compound of claim 6, wherein said 5-14 membered heterocyclic ring is selected from the group consisting of tetrahydrofuran, 1,3-dioxolane, 2,3-dihydrofuran, tetrahydropyran, benzofuran, isobenzofuran, 1,3-dihydro-isobenzofuran, isoxazole, 4,5-dihydroisoxazole, piperidine, pyrrolidine, pyrrolidin-2-one, pyrrole, pyridine, pyrimidine, octahydro-pyrrolo[3,4-b]pyridine, piperazine, pyrazine, morpholine, thiomorpholine, imidazole, imidazolidine-2,4-dione, benzimidazole, 1,3-dihydrobenzimidazol-2-one, indole, thiazole, benzothiazole, thiadiazole, thiophene, tetrahydro-thiophene 1,1-dioxide, diazepine, triazole, guanidine, diazabicyclo[2.2.1]heptane, 2,5-diazabicyclo[2.2.1]heptane, and 2,3,4,4a,9,9a-hexahydro-1H- β -carboline.
8. (currently amended) The compound of claim 5, wherein R^1 is H and R^2 is an aryl, ~~or a 5-14 membered heterocyclic ring containing one or more N, O or S~~ tetrahydrofuran, 1,3-dioxolane, 2,3-dihydrofuran, tetrahydropyran, benzofuran, isobenzofuran, 1,3-dihydro-isobenzofuran, isoxazole, 4,5-dihydroisoxazole, piperidine, pyrrolidine, pyrrolidin-2-one, pyrrole, pyridine, pyrimidine, octahydro-pyrrolo[3,4-b]pyridine, piperazine, pyrazine, morpholine, thiomorpholine, imidazole, imidazolidine-2,4-dione, benzimidazole, 1,3-dihydrobenzimidazol-2-one, indole, thiazole, benzothiazole, thiadiazole, thiophene, tetrahydro-thiophene 1,1-dioxide, diazepine, triazole, guanidine, diazabicyclo[2.2.1]heptane,

2,5-diazabicyclo[2.2.1]heptane, or 2,3,4,4a,9,9a-hexahydro-1H-β-carboline, each optionally substituted with an amino or another heterocyclic ring.

9. (canceled)

10. (currently amended) The compound of claim ~~[[5]]~~ 1, wherein W is NR¹R², and R¹ and R² ~~[[in NR¹R²]]~~ together with N form an optionally substituted 5-14 membered ring containing one or more N, O or S.

11. (original) The compound of claim 10, where NR¹R² is morpholine, thiomorpholine, piperazine, piperidine or diazepine.

12. (canceled)

13. (currently amended) The compound of claim ~~[[12]]~~ 1, wherein n is 2-3.

14. (currently amended) The compound of claim ~~[[12]]~~ 1, wherein NR³R⁴ is an acyclic amine, or guanidinyll or a tautomer thereof; ~~or R³ and R⁴ optionally form a substituted ring containing one or more N, O or S.~~

15. (currently amended) The compound of claim ~~[[12]]~~ 1, wherein ~~[[NR³R⁴ is]]~~ R³ and R⁴ together with N form an optionally substituted morpholine, thiomorpholine, imidazole, pyrrolidine, piperazine, pyridine or piperidine.

16. (currently amended) The compound of claim 1, wherein ~~[[Z]]~~ W is NR¹R²; and ~~W has the formula Z is~~



wherein R¹ and R² are as defined in claim 1;

~~R³ is H or C₁₋₆-alkyl;~~

~~n is 1-6; and~~

~~R⁴ is H or a C₁₋₁₀ alkyl or C₂₋₁₀ alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O and S, and optionally substituted with a carbocyclic or heterocyclic ring; and~~

~~wherein R¹ and R² in NR¹R²; and R³ and R⁴ together with N in NR³R⁴ each independently may form an optionally substituted ring.~~

17. (currently amended) The compound of claim 16, wherein ~~R¹ and R² in NR¹R²; and R³ and R⁴ in NR³R⁴ each independently together with N~~ form an optionally substituted ring containing one or more N, O or S morpholine, thiomorpholine, imidazole, pyrrolidine, piperazine, pyridine or piperidine.

18. (currently amended) The compound of claim ~~[[17]]~~ 19, wherein ~~[[Z is]]~~ said optionally substituted ring is optionally substituted with amino, carbamate, a C₁₋₁₀ alkyl containing one or more non-adjacent N, O or S, and optionally substituted with a heterocyclic ring; aryl or a saturated or unsaturated heterocyclic ring, ~~each of which is optionally substituted.~~

19. (currently amended) The compound of claim ~~[[17]]~~ 16, wherein ~~Z is substituted with a heterocyclic~~ R¹ and R² together with N in NR¹R² form an optionally substituted ring selected from the group consisting of tetrahydrofuran, 1,3-dioxolane, 2,3-dihydrofuran, tetrahydropyran, benzofuran, isobenzofuran, 1,3-dihydro-isobenzofuran, isoxazole, 4,5-dihydroisoxazole, piperidine, pyrrolidine, pyrrolidin-2-one, pyrrole, pyridine, pyrimidine, octahydro-pyrrolo[3,4-*b*]pyridine, piperazine, pyrazine, morpholine, thiomorpholine, imidazole, imidazolidine-2,4-dione, benzimidazole, 1,3-dihydrobenzimidazol-2-one, indole, thiazole, benzothiazole, thiadiazole, thiophene, tetrahydro-thiophene 1,1-dioxide, diazepine, triazole, guanidine, diazabicyclo[2.2.1]heptane, 2,5-diazabicyclo[2.2.1]heptane, and 2,3,4,4a,9,9a-hexahydro-1H- β -carboline.

20. (currently amended) The compound of claim ~~[[17]]~~ 19, wherein ~~Z and NR³R⁴ are independently~~ R¹ and R² together with N in NR¹R² form an optionally substituted morpholine, thiomorpholine, imidazole, pyrrolidine, piperazine, pyridine or piperidine.

21. (currently amended) The compound of claim ~~[[20]]~~ 17, wherein ~~Z and NR³R⁴ are~~ independently R³ and R⁴ together with N in NR³R⁴ form an optionally substituted pyrrolidine.



22. (currently amended) The compound of claim 21, wherein ~~[[Z]]~~ said pyrrolidine is substituted with pyrazine.









23. (canceled)



24. (original) The compound of claim 1, wherein each optionally substituted moiety is substituted with one or more halo, OR², NR¹R², carbamate, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, each optionally substituted by halo, =O, aryl or one or more heteroatoms; inorganic substituents, aryl, carbocyclic or a heterocyclic ring.

25. (original) The compound of claim 1, wherein said compound is chiral.

26. (currently amended) The compound of claim 1, wherein said compound is selected from the ~~compounds in Table 1~~ group consisting of:







and

27. (original) A pharmaceutical composition comprising the compound of claim 1, and a pharmaceutically acceptable carrier.

28. (withdrawn) A method for identifying a compound that interacts with a quadruplex-forming region of DNA, comprising

- contacting a nucleic acid capable of forming a quadruplex with a primer comprising a label to form a complex;
- contacting said complex with one or more test compounds and a polymerase to form a reaction mixture, and
- separating said reaction mixture by capillary electrophoresis to obtain one or more reaction products; and
- determining the extent of primer extension in said one or more reaction products.

29. (withdrawn) The method of claim 28, further comprising the step of determining the binding affinity of said one or more test compounds for said nucleic acid.

30. (withdrawn) The method of claim 28, wherein said label is a fluorescent label.

31. (currently amended) A method for ~~ameliorating~~ treating a cell proliferative disorder, comprising administering to a subject in need thereof an effective amount of the compound of claim 1 or a pharmaceutical composition thereof, thereby ~~ameliorating~~ treating said cell-proliferative disorder.

32. (original) The method of claim 31, wherein said cell proliferative disorder is cancer.

33. (original) The method of claim 31, wherein cell proliferation is reduced, or cell death is induced.

34. (original) The method of claim 31, wherein said subject is human or an animal.

35. (original) A method for reducing cell proliferation or inducing cell death, comprising contacting a system with an effective amount of the compound of claim 1 or a pharmaceutical composition thereof, thereby reducing cell proliferation or inducing cell death in said system.

36. (original) The method of claim 35, wherein said system is a cell or tissue.

37. (original) A method for reducing microbial titers, comprising contacting a system with an effective amount of the compound of claim 1 or a pharmaceutical composition thereof, thereby reducing microbial titers.

38. (original) The method of claim 37, where the system is a cell or tissue.

39. (original) The method of claim 37, wherein the microbial titers are viral, bacterial or fungal titers.

40. (currently amended) A method for ~~ameliorating~~ treating a microbial infection, comprising administering to a subject in need thereof an effective amount of the compound of claim 1 or a pharmaceutical composition thereof, thereby ~~ameliorating~~ treating said microbial infection.

41. (original) The method of claim 40, where the subject is a human or an animal.

42. (original) The method of claim 40, wherein said microbial infection is viral, bacterial or fungal.